Global Aspirin Enteric-Coated Tablets Market Size By Type (81mg/Pc, 100mg/Pc), By Application (Children, Adults), By Region, And Segment Forecasts, 2023 to 2032

The Global Aspirin Enteric-Coated Tablets Market was valued at USD 3.1 billion in 2023 and is projected to reach USD 4.9 billion by 2031, expanding at a CAGR of 5.9% during the forecast period (2023–2031). The market's growth is primarily driven by the rising prevalence of cardiovascular diseases, increasing adoption of preventive healthcare, and enhanced awareness regarding the gastrointestinal safety of enteric-coated formulations. Aspirin enteric-coated tablets are widely used for their anti-inflammatory, antipyretic, and antiplatelet properties, especially in long-term cardiovascular therapy. Their ability to minimize gastric irritation while maintaining therapeutic efficacy makes them a preferred option among healthcare providers and patients.

Drivers

1. Rising Incidence of Cardiovascular Diseases:

Cardiovascular diseases remain the leading cause of mortality globally. Enteric-coated aspirin is a cornerstone in secondary prevention strategies, particularly in reducing the risk of stroke and heart attack by inhibiting platelet aggregation.

2. Increased Preference for Preventive Medications:

There is a growing trend among both healthcare professionals and patients to use low-dose aspirin preventively in high-risk individuals. Enteric-coated versions offer a safer alternative for chronic use.

3. Growing Geriatric Population:

The elderly are more susceptible to heart diseases and are often prescribed aspirin. Enteric-coated formulations reduce the gastrointestinal side effects, enhancing compliance among this demographic.

Restraints

1. Risk of Gastrointestinal Bleeding in Certain Populations:

Despite being enteric-coated, aspirin still poses a bleeding risk, especially in elderly or those with pre-existing GI conditions, limiting its usage in certain populations.

2. Availability of Alternative Therapies:

The emergence of newer anticoagulants and anti-inflammatory drugs may challenge aspirin’s dominance, particularly in patients who require more targeted or safer options.

Opportunity

1. Expanding Preventive Care in Emerging Markets:

The increasing emphasis on preventive healthcare in countries such as India, China, and Brazil offers new opportunities for market penetration, especially through public health initiatives and awareness campaigns.

2. Innovations in Drug Delivery Technologies:

Continued R&D into advanced enteric-coating technologies that further reduce GI side effects and improve drug release profiles can attract a broader consumer base, including sensitive patient populations.

Market by System Type Insights

Based on product formulation, the Low-Dose (81 mg) Enteric-Coated Tablets segment held the largest market share in 2023. These tablets are widely prescribed for long-term cardiovascular protection, particularly among the elderly and those at high risk of cardiac events. They provide the optimal balance between efficacy and safety. The High-Dose Segment (325 mg and above), typically used for pain relief and anti-inflammatory purposes, is expected to witness modest growth due to increasing preference for safer alternatives in acute settings.

Market by End-use Insights

By end-use, the Retail Pharmacies segment dominated the global market in 2023, accounting for over 50% of the total revenue. The widespread availability and affordability of over-the-counter aspirin products contribute significantly to this segment’s strength. Meanwhile, Hospitals and Clinics are expected to show steady growth, driven by the increased prescription of aspirin for post-surgical cardiovascular care and long-term secondary prevention.

Market by Regional Insights

North America emerged as the leading regional market in 2023, owing to the high prevalence of lifestyle diseases, well-established healthcare systems, and growing consumer awareness. Europe follows closely, supported by favorable government health policies and higher geriatric populations. However, the Asia-Pacific region is projected to witness the highest CAGR during the forecast period, bolstered by rapid urbanization, improving healthcare access, and rising public health awareness.

Competitive Scenario

Key players in the Global Aspirin Enteric-Coated Tablets Market include Bayer AG, Dr. Reddy’s Laboratories, Cipla Inc., Teva Pharmaceuticals, Mylan N.V., Sun Pharmaceutical Industries Ltd., Sanofi S.A., Pfizer Inc., GlaxoSmithKline plc, and Novacyl. These companies are leveraging strategies such as product innovation, partnerships with healthcare providers, and expansion into emerging markets to sustain competitiveness.

Scope of Work – Global Aspirin Enteric-Coated Tablets Market

Key Market Developments

2023: Bayer AG launched a reformulated enteric-coated aspirin with enhanced bioavailability and reduced onset time for cardiovascular therapy.

2024: Teva Pharmaceuticals partnered with a leading telehealth provider to offer bundled preventive care kits that include enteric-coated aspirin.

2025: Dr. Reddy’s Laboratories announced a large-scale expansion into Southeast Asia, aiming to capture demand in emerging urban populations for low-cost preventive medications.

FAQs

What is the current market size of the Global Aspirin Enteric-Coated Tablets Market?

The market was valued at USD 3.1 billion in 2023.

What is the major growth driver of the Global Aspirin Enteric-Coated Tablets Market?

The primary growth driver is the rising prevalence of cardiovascular diseases and increasing preference for preventive medications.

Which is the largest region during the forecast period in the Global Aspirin Enteric-Coated Tablets Market?

North America is expected to maintain its leading position throughout the forecast period.

Which segment accounted for the largest market share in the Global Aspirin Enteric-Coated Tablets Market?

The Low-Dose (81 mg) segment dominated the market in 2023.

Who are the key market players in the Global Aspirin Enteric-Coated Tablets Market?

Major players include Bayer AG, Teva Pharmaceuticals, Dr. Reddy’s Laboratories, Cipla Inc., and Pfizer Inc.